Program
RBD7022
A development code. Also written as “RBD7022 injection”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 11 open or running | phase 1since Jul 10, 2025 | Jul 10, 2025 | none ahead |
| Suzhou Ribo Life Science | 10 open or running | phase 1since May 21, 2023 | May 21, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2023First study: phase 1 study in HyperlipidemiasNew to Suzhou Ribo Life ScienceSuzhou Ribo Life Science · NCT05912296 · 80 enrolled · China
- Jul 10, 2025Qilu Pharmaceutical's first study: phase 1 study in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-CNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07074236 · 48 planned · China
TargetBeta
“RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07074236Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C · China | 1 | Not yet recruiting | Qilu Pharmaceutical | Jan 2026 | 48 |
| NCT05912296Hyperlipidemias · China | 1 | Completed | Suzhou Ribo Life Science | Mar 4, 2025 | 80 |
How it is read
Names in the registry
- “RBD7022”, 2 entries
- “RBD7022 injection”, 1 entry
Codes read as this program: RBD7022.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 1 study
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.